490 related articles for article (PubMed ID: 11448486)
1. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.
Wagner JA; Járai Z; Bátkai S; Kunos G
Eur J Pharmacol; 2001 Jul; 423(2-3):203-10. PubMed ID: 11448486
[TBL] [Abstract][Full Text] [Related]
2. Mesenteric vasodilation mediated by endothelial anandamide receptors.
Wagner JA; Varga K; Járai Z; Kunos G
Hypertension; 1999 Jan; 33(1 Pt 2):429-34. PubMed ID: 9931142
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
Járai Z; Wagner JA; Varga K; Lake KD; Compton DR; Martin BR; Zimmer AM; Bonner TI; Buckley NE; Mezey E; Razdan RK; Zimmer A; Kunos G
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14136-41. PubMed ID: 10570211
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.
Lay L; Angus JA; Wright CE
Eur J Pharmacol; 2000 Mar; 391(1-2):151-61. PubMed ID: 10720647
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of anandamide hypotension by the transport inhibitor, AM404.
Calignano A; La Rana G; Beltramo M; Makriyannis A; Piomelli D
Eur J Pharmacol; 1997 Oct; 337(1):R1-2. PubMed ID: 9389389
[TBL] [Abstract][Full Text] [Related]
7. Changes in rat brain energetic metabolism after exposure to anandamide or Delta(9)-tetrahydrocannabinol.
Costa B; Colleoni M
Eur J Pharmacol; 2000 Apr; 395(1):1-7. PubMed ID: 10781666
[TBL] [Abstract][Full Text] [Related]
8. Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride].
Shivachar AC; Martin BR; Ellis EF
Biochem Pharmacol; 1996 Mar; 51(5):669-76. PubMed ID: 8615904
[TBL] [Abstract][Full Text] [Related]
9. Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats.
Ho WS; Gardiner SM
Br J Pharmacol; 2009 Jan; 156(1):94-104. PubMed ID: 19133994
[TBL] [Abstract][Full Text] [Related]
10. Hypotensive effect of anandamide through the activation of CB1 and VR1 spinal receptors in urethane-anesthetized rats.
del Carmen García M; Adler-Graschinsky E; Celuch SM
Naunyn Schmiedebergs Arch Pharmacol; 2003 Oct; 368(4):270-6. PubMed ID: 14504685
[TBL] [Abstract][Full Text] [Related]
11. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension.
Varga K; Wagner JA; Bridgen DT; Kunos G
FASEB J; 1998 Aug; 12(11):1035-44. PubMed ID: 9707176
[TBL] [Abstract][Full Text] [Related]
12. (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide.
Järbe TU; Lamb RJ; Lin S; Makriyannis A
Psychopharmacology (Berl); 2001 Aug; 156(4):369-80. PubMed ID: 11498713
[TBL] [Abstract][Full Text] [Related]
13. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity.
Wallace MJ; Martin BR; DeLorenzo RJ
Eur J Pharmacol; 2002 Oct; 452(3):295-301. PubMed ID: 12359270
[TBL] [Abstract][Full Text] [Related]
14. Effects of chronic nitric oxide synthase inhibition on the cardiovascular responses to cannabinoids in vivo and in vitro.
Wheal AJ; Bennett T; Randall MD; Gardiner SM
Br J Pharmacol; 2007 Mar; 150(5):662-71. PubMed ID: 17245361
[TBL] [Abstract][Full Text] [Related]
15. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
McCollum L; Howlett AC; Mukhopadhyay S
J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries.
White R; Ho WS; Bottrill FE; Ford WR; Hiley CR
Br J Pharmacol; 2001 Oct; 134(4):921-9. PubMed ID: 11606334
[TBL] [Abstract][Full Text] [Related]
17. Systemic and portal hemodynamic effects of anandamide.
Garcia N; Járai Z; Mirshahi F; Kunos G; Sanyal AJ
Am J Physiol Gastrointest Liver Physiol; 2001 Jan; 280(1):G14-20. PubMed ID: 11123193
[TBL] [Abstract][Full Text] [Related]
18. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain.
Burkey TH; Quock RM; Consroe P; Ehlert FJ; Hosohata Y; Roeske WR; Yamamura HI
Eur J Pharmacol; 1997 Oct; 336(2-3):295-8. PubMed ID: 9384246
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors.
Terranova JP; Michaud JC; Le Fur G; Soubrié P
Naunyn Schmiedebergs Arch Pharmacol; 1995 Nov; 352(5):576-9. PubMed ID: 8751088
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid.
Calignano A; La Rana G; Makriyannis A; Lin SY; Beltramo M; Piomelli D
Eur J Pharmacol; 1997 Dec; 340(2-3):R7-8. PubMed ID: 9537804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
